NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue ...

NASHVILLE, Tenn., Jan. 13, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA ® Dynamic Volume from the Teoxane RHA ® Collection for cheek augmentation and/or the correction of ...

According to the terms of the deal, Crown will buy Revance at $3.65 per share At the closing, Revance will no longer trade on the Nasdaq Revance’s portfolio includes Daxxify for injection and the RHA ...

Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock ...

We’re back again at AUSTEX Wellness & Medical Spa in Lakeway! We spoke with Laurel Belfiore, Founder & Owner, about dermal fillers which are a great anti-aging tool, but a lot of people are hesitant ...

Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...

RHA® Dynamic Volume delivers high patient satisfaction with youthful, attractive cheeks at rest and in motion.1 RHA® Dynamic Volume provides deep structural support while allowing for natural tissue ...